Jazz Pharmaceuticals plc
JAZZ
$181.37
-$0.65-0.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.88% | 4.14% | 4.52% | 5.76% | 6.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.88% | 4.14% | 4.52% | 5.76% | 6.12% |
| Cost of Revenue | 14.21% | 13.19% | 11.33% | 13.50% | 10.56% |
| Gross Profit | 3.92% | 3.23% | 3.85% | 5.01% | 5.69% |
| SG&A Expenses | 19.33% | 20.00% | 17.61% | 15.95% | 8.31% |
| Depreciation & Amortization | 4.36% | 3.85% | 2.51% | 1.92% | 3.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.79% | 9.05% | 6.38% | 7.14% | 6.20% |
| Operating Income | -7.07% | -15.49% | -3.84% | -0.75% | 5.82% |
| Income Before Tax | -234.12% | -277.48% | -273.25% | 51.88% | 58.92% |
| Income Tax Expenses | -197.98% | -403.44% | -8.24% | -30.12% | 23.75% |
| Earnings from Continuing Operations | -163.58% | -179.56% | -202.51% | 45.77% | 35.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.58% | -179.56% | -202.51% | 45.77% | 35.02% |
| EBIT | -7.07% | -15.49% | -3.84% | -0.75% | 5.82% |
| EBITDA | -1.38% | -6.15% | -0.22% | 0.90% | 4.68% |
| EPS Basic | -163.52% | -179.96% | -205.13% | 49.57% | 38.88% |
| Normalized Basic EPS | -0.26% | -12.91% | 6.62% | 13.48% | 19.99% |
| EPS Diluted | -167.97% | -185.51% | -215.61% | 54.76% | 43.64% |
| Normalized Diluted EPS | 1.44% | -7.86% | 15.69% | 19.99% | 30.79% |
| Average Basic Shares Outstanding | -1.39% | -2.41% | -2.78% | -2.54% | -2.29% |
| Average Diluted Shares Outstanding | -3.75% | -7.44% | -9.62% | -7.86% | -10.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |